US Patent Issued to Precision BioSciences on April 7 for "Engineered nucleases that target human and canine factor VIII genes as a treatment for hemophilia A" (North Carolina Inventors)

ALEXANDRIA, Va., April 7 -- United States Patent no. 12,595,470, issued on April 7, was assigned to Precision BioSciences Inc. (Durham, N.C.).

"Engineered nucleases that target human and canine factor VIII genes as a treatment for hemophilia A" was invented by Armin Hekele (Cary, N.C.), Clayton Beard (Durham, N.C.), Derek Jantz (Durham, N.C.), James Jefferson Smith (Morrisville, N.C.) and Victor Bartsevich (Durham, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene. The present invention also encompasses methods of using such engineered nucleases to make...